Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer


Select a different viewer

Citation:

See Citation Policies for referencing Mol*, RCSB PDB, PDB structures, and Computed Structure Models.